The use of urate-lowering therapy in patients with gout had neither beneficial nor adverse effects on long-term fracture risk.
The study authors retrospectively analyzed the charts of 4 chronic gout patients from a practice-based rheumatology clinic.
Ethnicity and hypertension have an association with incident gout that is not fully explained by differences in serum urate.
Investigators sought to examine the prevalence of CVD in patients with crystal-proven gout compared with control patients with arthritis.
Researchers found that the overall risk for hospitalization due to allopurinol-associated severe cutaneous adverse reactions is rare.
Addressing the challenges associated with clinical management of calcium pyrophosphate crystal deposition must start with understanding the unmet needs of associated joint damage and establishing a clearly defined strategy to address these needs.
Corticosteroids appear to be a reasonable alternative to NSAIDs for the treatment of acute pain as a result of gout.
Fenofibrate may be a valuable adjunct therapy in type 2 diabetes to reduce the burden of gout.
Investigators sought to determine whether allopurinol dose escalation is associated with all-cause mortality.
Ultrasound is a reliable diagnostic tool for identifying calcium pyrophosphate deposition disease.
Febuxostat is noninferior to allopurinol for rates of adverse CV events but is associated with higher all-cause and CV mortality in patients with gout and CVD.
Serum urate level is a strong predictor of incident gout, but only about half of patients with hyperuricemia develop clinically evident gout.
A patient with a history of uncontrolled gout presents with highly refractile, crystal-like macular lesions.
Risk for dementia may be increased with high serum uric acid levels in elderly individuals.
Assessing the relationship between gout and the metabolic syndrome may provide insight into the management of both conditions.
Higher Monosodium Urate Crystal Depositions With Greater Disease Severity in Allopurinol-Treated GoutDecember 08, 2017
In patients with gout who are treated with allopurinol, monosodium urate crystal depositions are higher with evidence of greater disease severity.
Febuxostat may lower blood pressure in patients with hyperuricemia, hypertension, and normal renal function.
New allopurinol use was associated with a reduced risk of incident peripheral arterial disease.
As the risk of developing gout is high in patients with hypertension, management of serum uric acid levels may improve patient outcomes.
A stepwise dose increase in febuxostat plus low-dose colchicine prophylaxis was effective in the reduction of gout flares compared with febuxostat alone.
A recent study assessed whether gout is a cardiovascular risk equivalent for stroke and myocardial infarction, similar to diabetes.
Gout medication febuxostat (Uloric) was associated with an increased risk of heart-related death and death from all causes.
The SSDM series of applications is cost-effective for patients of rheumatologists.
Machelle Manuel, PhD, discusses further gout treatment options to consider when target serum urate levels are not attained.
Despite rapidly lowering serum uric acid levels, lesinurad cannot be recommended alone at 400 mg per day, due to substantial adverse events.
A recent clinical trial has shown promising results that the drug febuxostat is effective at reducing gout flares in adults with early gout.
The US FDA has approved a new fixed-dose and dual-mechanism treatment option for uncontrolled gout.
Patients with tophaceous gout undergoing combination therapy with lesinurad and febuxostat showed a greater degree of symptom resolution than with febuxostat monotherapy.
Accidental patient dosing with Zurampic can potentially cause adverse renal effects such as acute renal failure; this is more common if Zurampic is given alone without a xanthine oxidase inhibitor.
Belief about medicines, presence of comorbidity, and being married positively influence adherence to medication.
Rheumatology Advisor Articles
- Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis
- Incident Gout Risk, Serum Urate, and Comorbidities: What Are the Links?
- Addressing Psychiatric Comorbidities in Inflammatory Rheumatic Diseases
- Clinician Roundtable: Improving Quality of Life in Systemic Lupus Erythematosus
- Incidence of Clinically Significant GI Events in NSAID-Treated Arthritis
- EULAR Releases Recommendations for Pain Management in OA, Inflammatory Arthritis
- Risk of Developing Herpes Zoster Increased in Rheumatoid Arthritis
- Supervised, Intense Exercise Improves Physical Fitness in Older Adults With RA
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- The Dorsal 4-Finger Technique: A New Method to Examine Joints in Rheumatoid Arthritis
- Gout, Urate-Lowering Therapy Not Associated With Risk for Fragility Fracture
- Does Exposure to Passive Smoke Increase Rheumatoid Arthritis Risk?
- Pegloticase Retreatment Effective for Gout After Gap in Therapy
- Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis
- Associations Between Site-Specific BMD, Anthropometric, Glucose Homeostasis Traits